Amprion has been awarded a $100,000 research grant to support studies on the causes of sporadic amyotrophic lateral sclerosis (ALS) that could help diagnose and develop potential therapies for the disease. The project, led by Richard Smith, MD, state director of the Center for Neurologic Study, and Amprion’s…
Amprion wins $100K to study causes of sporadic ALS
On a beautiful fall evening recently, my son had a junior varsity football game. I prepared to go by helping my husband, Todd, clear his lungs again in the bathroom, and then I set him up at his computer. He couldn’t go with me because he is paralyzed and…
A man with amyotrophic lateral sclerosis (ALS) recently became the first person to control an Amazon Alexa device with his thoughts, via an investigational, implanted brain-computer interface (BCI) from Synchron. The 64-year-old man, identified in a Synchron press release as Mark, lost the function of his upper…
Certain rare genetic variants associated with Parkinson’s disease and other neurodegenerative disorders may increase, by up to nearly four times, the risk of developing amyotrophic lateral sclerosis (ALS), a study found. These variations also may lead to faster ALS progression and shorter survival, so patients who carry the…
Last week I visited my dermatologist for my annual skin exam and when it was over I left his office with a brand new perspective about my ALS. I’m quite diligent about my annual medical exams — eye exams, regular ALS clinic visits, dental care, and in this case,…
RAG-17, an investigational therapy from Ractigen Therapeutics, was safe and well tolerated across all tested doses in people with amyotrophic lateral sclerosis (ALS) carrying mutations in the SOD1 gene — cases in which the disease is known as SOD1-ALS. Those are the findings of an investigator-initiated trial (NCT05903690)…
Quralis has completed dosing in the first group of healthy adults who volunteered for its Phase 1 clinical trial of QRL-101, an experimental oral small molecule being developed for amyotrophic lateral sclerosis (ALS). QRL-101-03 (NCT06532396) is expected to enroll about 60 volunteers who’ll be divided into five…
NRG Therapeutics has received a grant from the nonprofit Target ALS to advance preclinical studies of its new class of oral small molecules targeting mitochondria, the energy producers of cells, as a potential treatment for amyotrophic lateral sclerosis (ALS). The 2024 In Vivo Target Validation grant program, an…
A friend from a lifetime ago rolled down an accessible path leading to Lake Superior in my husband’s backup power wheelchair, and I experienced a sense of déjà vu after we turned down a boardwalk trail through the woods. My husband, Todd, was able to traverse this trail in McLain…
The U.S. Food and Drug Administration (FDA) has given the green light to Dr.Noah Biotech to initiate a Phase 1 clinical trial of NDC-011, a combination therapy for amyotrophic lateral sclerosis (ALS), in healthy volunteers. The trial, planned for the first half of 2025 at a single site…
Recent Posts
- Dealing with loss, both big and small, in life with ALS
- Scientists use fat-based ‘bubbles’ to sneak ALS treatment into the brain
- Guest Voice: ALS hasn’t stopped this go-to guy from showing up as ‘Dad’
- HEALEY ALS platform trial launches new arm testing oral therapy NUZ-001
- Ahead of this year’s MDA Conference, association’s CEO speaks of ‘hope’